At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Dorzolamide 2%-timolol 0.5% topical eyedropsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy
In Brief
A clinical study evaluating Dorzolamide 2%-timolol 0.5% topical eyedrops for Macular Hole and Retinal Detachment. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of this study is to see if glaucoma eye drops (dorzolamide-timolol) have any effect on the duration of an intraocular gas bubble following pars plana vitrectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Hole, Retinal Detachment
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedDec 2010
Primary CompletionJun 2013
TodayJul 2026
First PostedDec 10, 2010
Enrollment StartFeb 1, 2010
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.6 years ago
Interventions
Dorzolamide 2%-timolol 0.5% topical eyedropsdrug
Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.